Novel molecular pathways in Gorham disease: implications for treatment.
Rapid advances in evidence-based treatment schedules are a hallmark of modern oncology. In rare neoplastic diseases, however, clinical expertise is hard to build and evidence based on randomized trials almost impossible to collect. Gorham disease is a rare form of lymphatic proliferation accompanied by osteolysis, which usually occurs in young adults. Despite the fact that the clinical course of Gorham disease is often devastating and occasionally fatal, insights into its biological background are sparse and standardized treatment unavailable. Interestingly, recent knowledge on the mechanisms of lymphangiogenesis may help elucidate the pathophysiology of Gorham disease and lead to novel treatment targets. Here, we discuss our current understanding of Gorham disease, discuss established and emerging therapeutic strategies, and attempt to frame a treatment rationale.
Department of Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Jeroen
J
Hagendoorn
Torunn I
TI
Yock
Inne H M
IH
Borel Rinkes
Timothy P
TP
Padera
David H
DH
Ebb
D015415:Biomarkers / Q000097:blood; D001862:Bone Resorption / Q000209:etiology; D006801:Humans; D007150:Immunohistochemistry; D010015:Osteolysis, Essential / Q000209:etiology / Q000473:pathology / Q000628:therapy*
D015415:Biomarkers
Gorham disease; lymphangiogenesis; molecular biology; rare tumors; tumor biology; vascular malformations